Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proximod in Healthy Subjects and Patients With Rheumatoid Arthritis
NCT06361199Phase 1Completed
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Placebo with Proximod (2 arms). Primary endpoints: Peak Plasma Concentration up to 48 days, Time to Peak Plasma Concentration up to 48 days and 4 more. Started Dec 2021; status: completed.
02
Drugs
proximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06361199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361199.